Cadila v. Cadila: The Test That Defines Trademark Similarity in India

In 2001, the Supreme Court of India was asked a deceptively simple question: are the drug names “Falcitab” and “Falcigo” too similar? Both were medicines for falciparum malaria. Both were sold by companies carrying the Cadila name. The Court’s answer did far more than resolve a dispute between two pharmaceutical companies — it gave India the seven-factor test for deceptive similarity that courts still apply, in trademark cases across every industry, twenty-five years later.

Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd., reported at (2001) 5 SCC 73, is one of the most-cited trademark judgments in Indian law. For any founder choosing a brand name — especially in pharma, food, cosmetics, or any regulated category — the case is essential reading. It explains exactly how an Indian court decides whether your mark is too close to someone else’s, and why some industries face a much stricter standard than others. This is the deep-dive.

One judgment about two malaria drugs became the rulebook for every trademark dispute that followed.

The parties: one Cadila becomes two

The story starts with a corporate split. The original Cadila group, a major pharmaceutical business, was restructured. Out of that restructuring came two distinct companies — Cadila Healthcare Ltd. and Cadila Pharmaceuticals Ltd. Both were legitimately entitled to use the Cadila name as part of their corporate identity, a fact that made the later dispute unusual: this was not a copycat case.

Both companies operated in the same field — pharmaceuticals. Both, at the relevant time, developed a drug to treat falciparum malaria, a particularly dangerous form of the disease. And both gave their drug a brand name beginning with the same four letters.

The conflict: Falcitab vs Falcigo

Cadila Pharmaceuticals marketed its anti-malarial under the name “Falcigo”. Cadila Healthcare marketed its competing anti-malarial under the name “Falcitab”. Cadila Healthcare brought a passing-off action, arguing that “Falcitab” was deceptively similar to “Falcigo” and that the resemblance could confuse the trade and the public.

The lower courts were not persuaded. The trial court and the High Court declined to grant an interim injunction, reasoning broadly that the drugs were specialised medicines, that they would be prescribed and dispensed by trained professionals, and that the difference between the names was sufficient in that context.

The Supreme Court’s reasoning

On appeal, the Supreme Court took a different view of how the question should be approached — not necessarily of the final answer, but of the method. The Court’s central insight was that deceptive similarity cannot be assessed by a single yardstick. It depends on a combination of factors, and crucially, the standard should vary with the nature of the goods.

For ordinary consumer goods, a degree of imperfect recollection by an average buyer is the test. But for medicinal products, the Court reasoned, the stakes are different. Confusion between two drugs is not merely a commercial inconvenience — it can have consequences for health and life. The Court therefore held that pharmaceutical and medicinal marks deserve a stricter standard, and that even a likelihood of confusion that might be tolerated for ordinary goods should be guarded against more carefully for medicines.

Importantly, the Supreme Court did not itself grant an injunction. It set out the correct legal framework and directed the trial court to decide the matter expeditiously applying that framework. The enduring outcome of the case was not who won — it was the test.

The seven Cadila factors

The Court laid down the factors to be considered in deciding whether two marks are deceptively similar in a passing-off action:

1. The nature of the marks — whether they are word marks, label marks, or composite marks.
2. The degree of resemblance — phonetic similarity, visual similarity, and similarity in the idea conveyed.
3. The nature of the goods for which the marks are used.
4. The similarity in the nature, character and performance of the goods of the rival traders.
5. The class of purchasers likely to buy the goods — their education, intelligence, and the degree of care they exercise.
6. The mode of purchasing the goods or placing orders for them.
7. Any other surrounding circumstances relevant to the dissimilarity of the competing marks.

No single factor decides the question. A court weighs them together, against the background of the particular industry. The same weighing exercise drives Section 11 objections at examination — an examiner citing a similar earlier mark is making a preliminary version of this assessment.

What founders should learn

The Cadila judgment is not just legal history. It is a practical checklist for anyone naming a brand in India:

• Phonetic similarity is real risk, not a technicality. “Falcitab” and “Falcigo” differ in writing but share a dominant prefix and rhythm. Indian courts take phonetic resemblance seriously — especially how a name sounds when spoken aloud by an ordinary buyer.
• Your industry sets your standard. If you are in pharma, food, cosmetics, or any product where confusion can cause harm, you will be held to a stricter test. Choose a more distinctive name than you think you need.
• A shared prefix is a shared risk. Naming conventions that borrow a common descriptive prefix — especially one tied to the product’s function — multiply collision risk across an entire category.
• Even a legitimate name can collide. Both Cadilas had a genuine right to the Cadila name. Legitimacy of the root did not prevent a dispute over the product brand. Your corporate name being clean does not make your product name clean.
• Search before you commit. A proper similarity search — phonetic, visual, and conceptual — would surface a Falcigo before you printed Falcitab on a box.

Where this still applies in 2026

Twenty-five years on, the Cadila factors remain the working test Indian courts apply to deceptive similarity. The judgment is cited routinely in:

• Section 11 examination objections — when the Registry cites a similar earlier mark, the underlying logic is the Cadila weighing exercise.
• Opposition proceedings — opponents argue deceptive similarity using the seven factors.
• Infringement and passing-off suits — the factors structure the court’s analysis of whether confusion is likely.
• Brand clearance — competent practitioners screen new names against the Cadila standard before a client commits.

The modern wrinkle is that the “mode of purchasing” factor now includes e-commerce and quick-commerce. A drug or a supplement bought through an app, with autocomplete and search suggestions, presents confusion risks that did not exist in 2001. Courts increasingly read the Cadila factors in that updated context — which, if anything, makes a distinctive name more valuable, not less. Filing that distinctive name early is the practical takeaway.

The court did not decide who won. It decided how every future case would be judged.

People also ask

Frequently asked questions

What is the citation for the Cadila case?

Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd., reported at (2001) 5 SCC 73, decided by the Supreme Court of India. It remains one of the most-cited Indian trademark judgments.

How does the Cadila test affect trademark examination?

Examiners and courts apply the deceptive-similarity factors when assessing Section 11 conflicts. For pharmaceutical and medicinal marks especially, the stricter Cadila standard informs both examination objections and infringement decisions.

What is the difference between infringement and passing off?

Infringement under Section 29 protects a registered trademark and is easier to prove. Passing off is a common-law action protecting unregistered goodwill — it requires proving reputation, misrepresentation, and damage. Cadila was a passing-off case.

Does the Cadila test still apply after the 1999 Act?

Yes. The case was decided under the trademark regime as it then stood, but the seven-factor framework for deceptive similarity continues to be applied by Indian courts under the Trade Marks Act, 1999.

How can founders avoid a Cadila-style dispute?

Run a proper similarity search before adopting a brand name — phonetic, visual, and conceptual — especially in regulated categories like pharma, food, and cosmetics. A coined or arbitrary name carries far lower deceptive-similarity risk.

The cheapest way to win a Cadila-style case is to pick a name that never starts one.